The weekly injection was approved by the US Food and Drug Administration in 2017 for people with type 2 diabetes.

An anti-vaccine organization founded by HHS Secretary Robert F. Kennedy Jr. is urging the FDA he now oversees to pull the ...

"Considering the urgent global need for new gonorrhea treatments, the finding that a single-dose of oral zoliflodacin was efficacious at curing urogenital and rectal and pharyngeal gonorrhoea is ...

On December 5, 2025, four national food and beverage trade associations (the American Beverage Association, the Consumer ...

Treatment with neflamapimod slowed clinical worsening and led to reduced disease-related plasma biomarkers in individuals with dementia with Lewy bodies, according to a speaker at CTAD. “Dementia with ...

Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial ...

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...

In a closely watched case, the U.S. solicitor general urged the Supreme Court to review a controversy over so-called skinny ...

Tarlatamab-dlle received FDA approval for ES-SCLC after showing a 40% reduction in death risk compared with chemotherapy in the DeLLphi-304 trial. The trial demonstrated improved overall survival ...

The FDA has converted its accelerated approval to a standard one for tarlatamab in extensive-stage small cell lung cancer. The FDA has converted its 2024 accelerated approval of tarlatamab-dlle ...

WASHINGTON (AP) — Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about stroke, heart attack, dementia and other serious risks, the ...

Hormone therapies for menopause will no longer carry a black box warning about serious risks such as breast cancer, heart attack and stroke, the Food and Drug Administration announced Monday. In the ...